Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding

Lignende værker

• Interactions of 1263W94 with Other Antiviral Agents in Inhibition of Human Cytomegalovirus Replication
  af: Selleseth, Dean W., et al.
  Udgivet: (2003)
• Phase I Safety and Pharmacokinetic Trials of 1263W94, a Novel Oral Anti-Human Cytomegalovirus Agent, in Healthy and Human Immunodeficiency Virus-Infected Subjects
  af: Wang, Laurene H., et al.
  Udgivet: (2003)
• Preclinical and Toxicology Studies of 1263W94, a Potent and Selective Inhibitor of Human Cytomegalovirus Replication
  af: Koszalka, George W., et al.
  Udgivet: (2002)
• Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action
  af: Biron, Karen K., et al.
  Udgivet: (2002)
• Inhibition of Ganciclovir-Susceptible and -Resistant Human Cytomegalovirus Clinical Isolates by the Benzimidazole l-Riboside 1263W94
  af: McSharry, James J., et al.
  Udgivet: (2001)